 The hypothesis is that a belatacept-based immunosuppressive regimen with alemtuzumab induction, MMFMPA, and early glucocorticoid withdrawal Group A in renal transplant recipients or Belatacept-based immunosuppressive regimen with rabbit antithymocyte globulin induction, MMFMPA and early glucocorticoid withdrawal Group B will lead to less risk of graft loss, patient death, or reduced renal function at 12 months as compared to a tacrolimus-based immunosuppressive regimen with rabbit antithymocyte globulin, MMFMPA, and early glucocorticoid withdrawal in renal transplant recipients Group C. 